In a nutshell This article investigated the long-term safety and effectiveness of tandem autologous/allogeneic hematopoietic cell transplantation (auto/alloHCT) for patients with multiple myeloma (MM). The authors concluded that this therapy is safe and can improve the overall survival of these patients. Some background...
Read MoreCurrent disease status-Recurrent myeloma Posts on Medivizor
Evaluating ixazomib, cyclophosphamide and dexamethasone treatment for relapsed/refractory multiple myeloma
In a nutshell This article investigated the safety and effectiveness of combining ixazomib (Ninlaro), cyclophosphamide (Cytoxan) and dexamethasone (Decadron) for the treatment of relapsed or refractory (does not respond to treatment) multiple myeloma (RRMM). The authors concluded that the combination treatment is safe and gave...
Read MoreHow does elotuzumab affect pain and quality of life in non-responsive multiple myeloma?
In a nutshell This study investigated the effects of adding elotuzumab to lenalidomide and dexamethasone to treat un-responsive multiple myeloma. The main finding was that patients treated with elotuzumab responded better to lenalidomide and dexamethasone. Some background Many patients respond well to treatment for multiple myeloma (MM). However some...
Read MoreThe safety of elotuzumab, lenalidomide and dexamethasone in unresponsive multiple myeloma.
In a nutshell This paper compared the safety and effectiveness of elotuzumab (Empliciti) plus lenalidomide (Revlimid) and dexamethasone (Decadron) with lenalidomide and dexamethasone in unresponsive multiple myeloma. It was found that elotuzumab plus lenalidomide and dexamethasone was more effective than lenalidomide and dexamethasone alone. Some...
Read MoreAllogeneic transplant for multiple myeloma
In a nutshell This study examined the role of allogeneic hematopoietic stem cell transplantation in multiple myeloma. The study determined that allogeneic stem cell transplant is feasible for patients who have previously received other treatment. Some background Survival of patients with multiple myeloma has improved with the development of new...
Read MoreCarfilzomib – once weekly or twice weekly to treat unresponsive multiple myeloma?
In a nutshell This study investigated the safety and effectiveness of two different doses of carfilzomib (Kyprolis) for patients with relapsed or refractory multiple myeloma. This study concluded that once weekly carfilzomib is safe and more effective than the twice weekly dose for these patients. Some background Multiple myeloma is a type of cancer...
Read MoreDaratumumab with bortezomib and dexamethasone in Japanese patients
In a nutshell This paper compared the safety and effectiveness of daratumumab (Darzalex) in combination with bortezomib (Velcade) and dexamethasone (Ozurdex) in patients with relapsed or refractory multiple myeloma. Some background Multiple myeloma is a cancer of the plasma cells of the blood. Multiple myeloma can be refractory (not responding...
Read MoreNew treatments for induction with stem cell transplant in relapsed multiple myeloma
In a nutshell This paper studied the use of novel drugs with salvage autologous stem cell transplant in relapsed multiple myeloma. This study concluded that salvage autologous stem cell transplant is safe and effective for patients with relapsed multiple myeloma. Some background For patients with newly diagnosed multiple myeloma aged up to...
Read MoreMarizomib, pomalidomide and dexamethasone in relapsed or refractory multiple myeloma
In a nutshell This paper studied the safety and efficacy of marizomib, pomalidomide (Pomalyst) and dexamethasone (Ozurdex) in the treatment of relapsed or refractory multiple myeloma. The authors concluded the treatment was well tolerated and effective. Some background Multiple myeloma is a cancer of the plasma cells (type of...
Read MoreEffectiveness of venetoclax in relapsed or refractory multiple myeloma
In a nutshell This paper studied the effectiveness of venetoclax (Venclexta) for the treatment of relapsed or refractory multiple myeloma. Venetoclax at a daily dose up to 1200 mg showed promise in treating patients with relapsed or refractory multiple myeloma with the t(11;14) genetic mutation. Some background Multiple myeloma is a cancer...
Read MoreTreatment combinations for multiple myeloma patients with the 17p deletion
In a nutshell This study analyzed the results of 13 separate studies on treatment combinations for multiple myeloma patients with the 17p deletion. This study concluded that bortezomib-based primary and maintenance therapy improved outcomes in newly diagnosed patients with the 17p deletion. The combination...
Read MoreLooking for patients with relapsed/refractory multiple myeloma to test the safety and effectiveness of isatuximab
In a nutshell This phase 1 clinical trial will test the safety of isatuximab (SAR650984) in patients with relapsed or refractory multiple myeloma, as well as the effectiveness of isatuximab in multiple myeloma patients who have been previously treated with daratumumab (Darzalex). The primary outcome will be measured by side effects and overall...
Read More
